A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects.

Completed

• Conditions: Asthma; 10010613

• Registration Number: NL-OMON35064
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

- healthy male volunteers
- age between 18 and 50 years
- body weight is 50 kg or more and BMI is between 18.5 and 29.9 kg/m2
- non smoker (have not smoked for at least 6 months and/or have not smoked for a period of 10 years with a maximum of 10 cigarettes or equivalent per day or a period of 5 years with a maximum of 20 cigarettes or equivalent per day prior to study drug administration

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics : plasma and urine GSK2239633 concentrations, pharmacokinetic<br /><br>parameters<br /><br>Radiokinetics : total radioactivity in plasma and urine</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n/a</p><br>